Evidence map›Paper›PMID 26961929›Full record

Trial reportThe American journal of clinical nutrition2016

Effect of ω-3 supplementation on placental lipid metabolism in overweight and obese women.

Virtu Calabuig-Navarro, Michelle Puchowicz, Patricia Glazebrook, Maricela Haghiac, Judi Minium, Patrick Catalano, Sylvie Hauguel deMouzon, Perrie O'Tierney-Ginn

2 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of clinical nutrition, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 41 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 3 pooled it
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00957476 nacompletednot on this map

Omega-3 Supplementation Decreases Inflammation and Fetal Obesity in Pregnancy

TypeinterventionalSponsorMetroHealth Medical CenterRan2009 to 2013Enrolled72ConditionsInflammation, Obesity, Pregnancy, Fetal GrowthArmsOmega-3 Fish Oil
NCT03146156 nacompletednot on this mapstarted 2017, after this paper: background citation

Lifestyle Intervention in Preparation for Pregnancy (LIPP)

TypeinterventionalSponsorTufts Medical CenterRan2017 to 2025Enrolled99ConditionsObesity, Lifestyle-related Condition, Macrosomia, FetalArmsLifestyle Intervention
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Omega-3 fatty acid addition during pregnancy.The Cochrane database of systematic reviews · 2018
    Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Virtu Calabuig-Navarro
Michelle Puchowicz
Patricia Glazebrook
Maricela Haghiac
Judi Minium
Patrick Catalano
Sylvie Hauguel deMouzon
Perrie O'Tierney-Ginn
MetroHealth · USCase Western Reserve University · US

Funding

OMEGA-3 SUPPLMENTATION DECREASES INFLAMMATION AND FETAL OBESITY IN PREGNANCYR01HD057236 · NICHD · CASE WESTERN RESERVE UNIVERSITY · PI CATALANO, PATRICK, HAUGUEL-DE MOUZON, SYLVIE · 2009 to 2010
$1.6M
Maternal obesity depresses essential fatty acid transport in the placentaR00HD062841 · NICHD · METROHEALTH MEDICAL CENTER · PI O'TIERNEY-GINN, PERRIE F · 2013 to 2015
$710k
NICHD NIH HHS R00 HD062841NICHD NIH HHS R01 HD057236
6 · The paper itself

Abstract

backgroundThe placentas of obese women accumulate lipids that may alter fetal lipid exposure. The long-chain omega-3 fatty acids (n–3 FAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) alter FA metabolism in hepatocytes, although their effect on the placenta is poorly understood.

objectiveWe aimed to investigate whether n–3 supplementation during pregnancy affects lipid metabolism in the placentas of overweight and obese women at term.

designA secondary analysis of a double-blind randomized controlled trial was conducted in healthy overweight and obese pregnant women who were randomly assigned to DHA plus EPA (2 g/d) or placebo twice a day from early pregnancy to term. Placental FA uptake, esterification, and oxidation pathways were studied by measuring the expression of key genes in the placental tissue of women supplemented with placebo and n–3 and in vitro in isolated trophoblast cells in response to DHA and EPA treatment.

resultsTotal lipid content was significantly lower in the placentas of overweight and obese women supplemented with n–3 FAs than in those supplemented with placebo (14.14 ± 1.03 compared with 19.63 ± 1.45 mg lipid/g tissue; P < 0.05). The messenger RNA expression of placental FA synthase (FAS) and diacylglycerol O-acyltransferase 1 (DGAT1) was negatively correlated with maternal plasma enrichment in DHA and EPA (P < 0.05). The expression of placental peroxisome proliferator–activated receptor γ (r = −0.39, P = 0.04) and its target genes DGAT1 (r = −0.37, P = 0.02) and PLIN2 (r = −0.38, P = 0.04) significantly decreased, with an increasing maternal n–3:n–6 ratio (representing the n–3 status) near the end of pregnancy. The expression of genes that regulate FA oxidation or uptake was not changed. Birth weight and length were significantly higher in the offspring of n–3-supplemented women than in those in the placebo group (P < 0.05), but no differences in the ponderal index were observed. Supplementation of n–3 significantly decreased FA esterification in isolated trophoblasts without affecting FA oxidation.

conclusionSupplementing overweight and obese women with n–3 FAs during pregnancy inhibited the ability of the placenta to esterify and store lipids. This trial was registered at clinicaltrials.gov as NCT00957476.

Indexed as

AdultBody Mass IndexDietary SupplementsDocosahexaenoic AcidsDouble-Blind MethodEicosapentaenoic AcidFemaleHumansLipid MetabolismObesityOverweightPlacentaPPAR gammaPregnancyRNA, MessengerTrophoblastsDocosahexaenoic AcidsEicosapentaenoic AcidPPAR gammaRNA, Messenger

Identifiers

PMID26961929
PMCPMC4807706
OpenAlexW2293178446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.